Entrada Therapeutics (TRDA) Change in Accured Expenses (2020 - 2026)

Entrada Therapeutics' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$6.0 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 9.03% year-over-year to -$6.0 million in Q1 2026; TTM through Mar 2026 was $4.2 million, a 445.73% increase from a year earlier, with the FY2025 full-year figure at $4.7 million, up 177.63% from the prior year.
• Change in Accured Expenses declined to -$6.0 million in Q1 2026 per TRDA's latest filing, from $2.2 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $6.9 million in Q3 2022 and bottomed at -$6.0 million in Q1 2026.
• The 5-year median for Change in Accured Expenses is $1.6 million (2024), against an average of $357176.5.
• Across the five-year window, Change in Accured Expenses slumped 795.59% in 2023 and soared 605.88% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at -$4.3 million in 2022, then soared by 145.03% to $2.0 million in 2023, then plunged by 121.74% to -$425000.0 in 2024, then surged by 605.88% to $2.2 million in 2025, then plunged by 376.84% to -$6.0 million in 2026.
• Per Business Quant, the three latest TRDA Change in Accured Expenses figures stand at -$6.0 million (Q1 2026), $2.2 million (Q4 2025), and $3.7 million (Q3 2025).